Healthcare Industry Insights: 2020

Friday, 13 November 2020

Ambulatory Surgery Center Market Report | 6.1% CAGR Growth till 2026

The global Ambulatory Surgery Centers Market size is expected to reach USD 120.8 billion by 2026, based on a new report by Grand View Research, Inc., exhibiting a 6.1% CAGR during the forecast period. Increase in incidence of chronic diseases and rise in geriatric population have furthered the demand for ambulatory surgery centers. Furthermore, advancements in surgeries, such as endoscopy and laparoscopy, are expected to propel ASC market growth.

The number of patient admissions is slowly decreasing owing to increasing outpatient visits. This is primarily due to high hospitalization cost and adoption of technologically advanced techniques in outpatient centers, making treatment fast and cost-effective. Advanced surgical methods allow tests and procedures to be performed without hospital admission. According to the American Hospital Association, the total number of outpatient admissions increased from 624 million in 2008 to 675 million in 2012. The number of inpatient admissions decreased from 35.76 million in 2008 to 34.40 million in 2012.

In May 2016, some new codes were added to the coverage for outpatient services in U.S., such as that for gynecology, adenoidectomy, and tonsillectomy. Hence, supportive reimbursement scenario is anticipated to boost market growth.

North America held the dominant share in 2018, driven primarily by U.S. Leading market players in the country are acquiring ambulatory services to provide technologically advanced surgeries and treatments, further propelling demand for ambulatory and primary care services. Asia Pacific is likely to emerge as a strong contender in the global scenario. Some of the prominent players in this region are Surgery Center of Melbourne, Nova Medical Centers, Kaiser Permanente, The Indian Association of Day Surgery, Memorial Sloan Kettering, M D Anderson Cancer Center, and The Mumbai Surgical Society.

Request a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/ambulatory-surgery-center-asc-market

Further key findings from the study suggest:

In 2018, gastroenterology accounted for the largest share in the market by application. This can be attributed to surge in visits to ambulatory care centers for treatment of gastrointestinal diseases. It is one of the most common surgical specialties in single- or multi-specialty ASCs
Plastic surgery is anticipated to observe the fastest growth in the coming years due to rise in disposable income and growing preference for private care facilities in comparison with hospital surgery centers for plastic surgery. Time and cost advantages, as well as expertise offered by these ambulatory centers, are anticipated to boost demand for plastic surgeries in these settings
North America dominated the market in 2018 thanks to increased government funding focused on transforming primary care services and rise in coverage for outpatient services
Asia Pacific is expected to witness lucrative growth in the coming years owing to presence of developing economies, increasing awareness about ASCs, and investments by international players
Key players in the market include Envision Healthcare Corporation; Terveystalo; Tenet Healthcare Corporation; MEDNAX Services, Inc.; TeamHealth, Quorum Health Corporation; UnitedHealth Group; Surgery Partners; Community Health Systems, Inc.; and Healthway Medical Group.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Europe Hyaluronic Acid Based Dermal Fillers Market by Allergan; Galderma Laboratories; Merz Pharma; Genzyme Corporation

The Europe Hyaluronic Acid Based Dermal Fillers Market size is expected to reach USD 1.4 billion by 2026, according to a new report by Grand View Research Inc., exhibiting a CAGR of 7.6% over the forecast period. Rapidly aging population, large number of cosmetic surgeries performed, and technological advancements are among key factors driving the market. Growing demand to enhance one’s aesthetic appeal is resulting in high number of cosmetic surgeries being performed. This can also be attributed to the availability of noninvasive surgical alternatives and rising awareness among consumers. According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2017, hyaluronic acid-based dermal filler procedures were among the three most preferred noninvasive aesthetic surgeries.

Minimal adverse effects, lesser pain, shorter recovery time, and fewer postsurgical complications are some of the factors driving preference for minimally invasive surgeries. The European market is dominated by well-known brands such as Juvederm, Restylane, and Belotero. In addition, France has several native brands with different patented technologies, thereby contributing to regional market growth. Stylage, Cytosial, Hyaluronica, and Surface Volume are some of the local brands available in the market.

Increasing demand for aesthetic procedures majorly in Italy and Spain is creating a great opportunity for market expansion. According to the ISAPS, about 952,830 aesthetic surgeries were performed in 2016, of which 650,995 were noninvasive procedures such as Botox and dermal fillers.

Various strategic initiatives such as product launch, approvals, and mergers and acquisitions propel the market. For instance, in January 2017, Allergan plc launched Juvederm VOLITE, a new hyaluronic acid dermal filler with its unique patented VYCROSS technology, which lasts for up to nine months. In another instance, in September 2018, Allergan acquired Bonti, Inc. to expand its product portfolio with Bonti’s pipeline products such as (BoNT/E) botulinum neurotoxin serotype E in phase II, EB-001T (therapeutic), and EB-001A (aesthetic).

Request a free sample copy or view report summary: Europe Hyaluronic Acid Based Dermal Fillers Market Report

Europe Hyaluronic Acid Based Dermal Fillers Market Report Highlights

Increase in per capita income in countries such as Germany, Italy, France, and Spain is a key factor driving the adoption of dermal fillers. Rapid advancements in dermal filler technology have resulted in better results in lesser time and at lower costs
In 2018, single-phase products dominated the market owing to technological advancements, wide range of applications, and rise in applications of implantable devices
By application, the wrinkle removal segment is anticipated to grow at the fastest rate during the forecast period. Hyaluronic acid dermal fillers are gaining popularity in varied antiaging treatments as they help save time. A general hyaluronic acid anti-wrinkle treatment procedure takes less than an hour and the average cost is approximately USD 600
Italy dominated the regional market in 2018 owing to technological advancements in the region and introduction of new products by prominent manufacturers
Some of the key players in this industry are Allergan; Galderma Laboratories; Merz Pharma; Genzyme Corporation; Medicis Pharmaceutical; Inamed Corporation; Anika Therapeutics, Inc.; Laboratoires VIVACY; Bioxis Pharmaceuticals; and Bohus Biotech AB.

Cannabis Extract Market Trends, Segmentation and Future Scope

The global Cannabis Extract Market size is expected to be valued at USD 28.5 billion by 2027, according to a new report published by Grand View Research, Inc. It is projected to expand at a CAGR of 16.6% over the forecast period. Growing legalization of cannabis in various countries, preference for cannabis oil and tinctures, and adoption of medical marijuana for treating chronic diseases like arthritis, anxiety, and Alzheimer’s are the major factors propelling the growth.

Cannabis extracts have gained wide recognition in recent years and are expected to provide impetus to cannabis market growth. Based on product type, cannabis extracts are classified into oils and tinctures. The oils segment is expected to dominate the market in 2019 with a revenue of USD 4.8 billion and is anticipated to witness the fastest CAGR of 17.5%, over the forecast period.

Based on extract type, the market is segmented into full spectrum cannabis extracts and cannabis isolates. The full spectrum cannabis extracts dominated the market in 2019, with a revenue of USD 4.3 billion, owing to the added advantage of the entourage effect. Various manufacturers prefer full spectrum cannabis products owing to their advantages over the isolates. Thus, the segment is expected to remain dominant over the forecast period.

Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/cannabis-extract-market

Further key findings from the report suggest:

In 2019, oils held the largest revenue share of 66.5% owing to ease of availability and low price of the product
The full spectrum segment was valued at USD 4.3 billion in 2019, owing to its entourage effect-a synergistic relationship between cannabinoids and terpenes that exhibits an increase in the healing properties of each cannabinoid
Marijuana isolates is anticipated to emerge as the second largest type segment over the forecast period, owing to several advantages that have increased its adoption. For instance, the purest form of isolates, such as CBD oil, have no psychoactive effects as they have no THC content
In 2019, North America accounted for the largest share in the global cannabis concentrates market. This can be attributed to high utilization owing to government approvals
Key players operating in the cannabis extract market include Canopy Growth Corporation; Aphria Inc.; Aurora Cannabis; Maricann Inc.; Tilray; Organigram Holdings Inc.; Tikun Olam, Ltd.; and The Cronos Group

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Wednesday, 11 November 2020

Intravascular Catheters Market by Forecast to 2025 with Leading Key Players: Boston Scientific Corporation; C.R. Bard, Inc.; Johnson & Johnson Services, Inc.

The global Intravascular Catheters Market size is expected to reach USD 8.8 billion by 2025, according to a new report by Grand View Research, Inc., registering an 11.8% CAGR during the forecast period. Increasing number of surgical procedures requiring catheters, growing awareness about hospital-acquired infections, and increasing coverage of healthcare insurance are some of the factors contributing to the demand for intravascular catheters from 2019 to 2025. The market is also expected to be driven by increasing number of patients undergoing cardiovascular as well as urological procedures and rising incidents of trauma injuries.

Short Peripheral Intravascular Catheters (PIVC) dominated the market with a revenue of USD 2.8 billion in 2018, on account of lower infection risk associated with these products. In addition, short PIVCs are preferred over other catheters due to their quick discharge and short dwelling time. This product segment is expected to witness lucrative CAGR between 2018 to 2025 as a consequence of increasing concerns over catheter-associated bloodstream infections leading to catheter colonization.

Hospitals dominated the market on the basis of end use in 2018, with a revenue of USD 2.5 billion. The trend is likely to continue over the forecast period owing to increase in number of surgical procedures requiring catheters, growing health insurance coverage, and rising hospital admissions. Ambulatory Surgical Centers (ASC) are anticipated to witness the fastest growth, with a CAGR of 13.5% through 2025. Surgical procedures are cheaper in ASCs as compared to hospitals. As a result, the market is expected to witness a rise in adoption of surgical procedures in ASCs, which in turn is anticipated to drive demand for intravascular catheters over the forecast period.

Asia Pacific dominated the intravascular catheters market with a revenue of USD 1.2 billion in 2018, owing to high patient base, increasing investments in healthcare infrastructure, growing insurance coverage, and availability of reimbursements. This region is anticipated to witness lucrative growth due to its high potential in overcoming unmet medical needs among patients suffering from cardiovascular and urological diseases as well as trauma injuries. China dominated the APAC market with a 23.3% revenue share in 2018 owing to high unmet medical needs, growing awareness about hospital-acquired infections, and increase in healthcare accessibility. Thus, a high population base with unmet medical needs is expected to drive demand for intravascular catheters between 2018 to 2025.

Request a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/intravascular-catheters-market

Further key findings from the report suggest:

Asia Pacific dominated the market in 2018 with a revenue of USD 1.2 billion, owing to factors such as large patient base, growing awareness regarding hospital-acquired infections, increase in healthcare access, and expanding healthcare coverage
U.S. is the largest country with an incremental opportunity of USD 542.0 million from 2019 to 2025
The hospitals segment dominated the market by end use in 2018 owing to growing number of surgical procedures requiring intravascular catheters and increasing hospital admissions
Some of the key players in this market are Boston Scientific Corporation; C.R. Bard, Inc.; Johnson & Johnson Services, Inc.; Abbott; Coloplast Ltd; Smith Medical; Edwards Lifesciences Corporation; Medtronic; McKesson Medical Surgical Inc.; and TERUMO CORPORATION.

About Us:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Hunter Syndrome Treatment Market 2026 | Industry Analysis by GC Pharma, Sangamo Therapeutics, Inc.; JCR Pharmaceuticals Co Ltd.

The global Hunter Syndrome Treatment Market size is expected to reach a value of USD 1.52 billion by 2026, expanding at a CAGR of 7.1%, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period.

Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According to the data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 to 150,000 male births.

Presently, there are no approved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc’s Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea.

Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected to significantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA’s Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment.

Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/hunter-syndrome-treatment-market

Further Key Findings from the Study Suggest:

The enzyme replacement therapy segment has acquired the largest share in 2018, owing to the increased adoption of Elaprase and the potential approval of Hunterase worldwide
The absence of curative therapies for MPS II creates lucrative opportunities for the key players in the market for developing new therapies
The launch of late-stage pipeline therapies is expected to drive the market growth during the forecast period
Currently, Shire Plc. is one of the leading players, supported by strong sales of their marketed drug ELAPRASE for the disease treatment
Major players in the market are adopting inorganic growth strategies such as partnerships and collaborations for the development and commercialization of novel therapies
In 2018, North America held a dominant position in the global market, owing to favorable reimbursement scenario, high awareness regarding rare disorders, and presence of major players
Some of the key companies in hunter syndrome treatment market include GC Pharma, Sangamo Therapeutics, Inc.; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.; and Shire Plc. (Takeda Pharmaceutical Company)

Diabetic Foot Ulcer Treatment Market Analysis, Scope, Growth Opportunities and Forecast Report till 2025

The global Diabetic Foot Ulcer Treatment Market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.2% during the forecast period. Rising prevalence of diabetes, increasing healthcare expenses, and rapidly growing geriatric population worldwide are some of the major factors driving the diabetic foot ulcer treatment market.

Diabetic foot ulcers are one of the most common foot injuries that is caused due to diabetes mellitus. Management of diabetic foot ulcers aims at fast healing and wound closure, by adopting a multidisciplinary therapeutic approach so as to avoid amputation. Among different types of treatment options available, biologics held the largest share in the diabetic foot ulcer treatment market in 2017. This can be attributed to strong revenue generated by growth factors that are prescribed worldwide for their ability to promote generation of new cells and achieve wound closure. Therapy devices and wound care dressings also offer significant commercial opportunity due to their cost-effectiveness, ease of availability, and wide use in combination with other treatments at every level of wound care management.

Among different ulcer types, neuro-ischemic ulcers led the market in 2017 with more than 50.0% market share due to higher patient population suffering from the ulcer type globally. North America represented the largest share in the global market in 2017 owing to rising prevalence of diabetes, growing geriatric cohort, increased investment in R&D of novel therapies, and developed healthcare facilities.

Request a free sample copy or view report summary: Diabetic Foot Ulcer Treatment Market Report

Diabetic Foot Ulcer Treatment Market Report Highlights

The biologics segment commanded the largest share in 2017 and is projected to retain its position through the forecast period, due to increased adoption and potential approvals of growth factors
North America dominated the DFU treatment market in 2017 due to well-established favorable healthcare reimbursements and infrastructure
Asia Pacific is expected to witness the fastest growth owing to expanding diabetes patient population driven by increasing healthcare expenses and growing geriatric cohort
The neuro-ischemic ulcers segment accounted for the leading share in 2017. It is likely to experience the fastest growth during the forecast period
The foam and alginate dressings, skin grafts, and negative pressure wound therapy segments are anticipated to exhibit significant CAGR over the forecast period
Some of the key players in this space are ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; and BSN Medical GMBH.

Hereditary Angioedema Therapeutics Market Report | 8.1% CAGR Growth till 2026

The global Hereditary Angioedema Therapeutic Market size is expected to reach USD 4.2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting an 8.1% CAGR during the forecast period. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China’s National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

Request a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/hereditary-angioedema-hae-therapeutics-market

Further key findings from the report suggest:

The C1-esterase inhibitor segment held the largest share in 2018 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE
On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment
Based on route of administration, intravenous drug therapies was one of the largest segments. Subcutaneously-administered therapies, on the other hand, are estimated to exhibit a lucrative CAGR of over 9.0% during the forecast period owing to benefits such as convenient dosing and improved drug effectiveness
North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2018. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market
Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region
Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.

Tuesday, 10 November 2020

US Urgent Care Market Trends, Segmentation and Future Scope

The U.S. Urgent Care Market size is expected to reach USD 30.6 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 6.2% CAGR during the forecast period. Increase in incidence of chronic diseases, rising affordability of emergency care, and growing demand for cost-effective treatment for geriatric population are factors likely to drive the market during the forecast period.

The U.S. urgent care market is expected to witness high growth in the coming years due to increasing investments by service providers and growing recognition and need to provide affordable care. In addition, growing medical coverage is anticipated to propel market growth. According to the Patient Protection and Affordable Care (PPAC) Act, 2010, approximately 32 million individuals were insured in U.S.

Various strategic initiatives such as partnerships, collaborations, mergers and acquisitions are likely to boost the urgent care market. For instance, in June 2018, CityMD acquired STAT Health to expand its services to 100 locations in New York City. This acquisition is expected to help address healthcare challenges and provide coordinated care.

Hospitals are increasing their interest in UC centers to maintain the balance between emergency and primary care in hospitals. UC centers now possess tools for diagnosis, blood testing, screening, radiology. Companies and the U.S. government, in collaboration with UC centers, organize certain wellness programs for improvement of health status of the nation’s population. Introduction of telemedicine is assisting these centers and enabling comfortable consultation for acute conditions.

Request a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/us-urgent-care-market

Further key findings from the report suggest:

· In U.S., injury is one of the major causes of death among children and is subsequently anticipated to increase demand for urgent care. According to the Centers for Disease Control and Prevention (CDC), in 2016, about 32,074,270 injuries were reported in the country

· By application, acute respiratory infection accounted for the largest share in the market in 2017 due to treatment at low cost for infections such as asthma, bronchitis, cough, nausea, and sore throat

· The hospital-owned segment, supported by joint ventures with hospitals, accounted for the largest share in the market and is anticipated to maintain its dominance over the forecast period due to easy follow-up with specialists and physicians

· Some of the key players are Concentra, Inc.; Urgent Care MSO, LLC; American Family Care; CareNow; City Practice Group of New York; CareSpot; Fast Pace Urgent Care; Centra Care; Physicians Immediate Care; Intermountain Healthcare; Aurora Health Care; Urgent Team; Prohealth; MD Now; Hometown Urgent Care; NextCare Holdings, Inc.; and MedSpring.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com